Booster HPV vaccine study for recurrent respiratory papillomatosis
Treatments studied
Part of Ear, nose & throat, Infections clinical trials.
This trial tests whether a booster shot of the Gardasil-9 vaccine can help adults with recurrent respiratory papillomatosis (RRP) go longer between treatments. If you've already had the full vaccine series more than two years ago and still have RRP flare-ups, this booster might reduce how often you need surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- You completed the Gardasil-9 vaccine series (2 or 3 shots) more than 2 years ago
- You have been diagnosed with recurrent respiratory papillomatosis (RRP)
- You still get papilloma growths that need treatment
- You have had at least 2 treatments for RRP since finishing the vaccine series
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines two drugs, bevacizumab (Avastin) and PRGN-2012, to see if they control throat and airway growths linked to recurrent respiratory papillomatosis. You must have already tried PRGN-2012 before.
This Phase 1 trial is testing a vaccine made from your own immune cells (dendritic cells) that may help your body fight the virus causing recurrent papillomas in your voice box. It is for people whose papillomas are caused by HPV type 6, who have had at least one recurrence in the past year.
This Phase 4 study tests whether a 9-type HPV vaccine (9vHPV) can reduce how infectious HPV is and lower the chance of HPV spreading in women who already have HPV16 and/or HPV18. It focuses on specific HPV-positive women recently diagnosed and compares what happens after vaccination.
This study is for people with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. Doctors will follow your health over time and study the condition to learn more about how it progresses.
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
Hear when a new Recurrent Respiratory Papillomatosis (RRP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.